Although efgartigimod is approved for the treatment of AChR-antibody positive MG, growing evidence indicated that it was also well-tolerated and efficacious in MuSK-antibody positive and triple-negative gMG patients (17, 22–24). The gene discussed is MUSK; the disease is myasthenia gravis.